

## Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

San Diego, March 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the 33<sup>rd</sup> Annual Oppenheimer Healthcare Conference on Wednesday, March 15, 2023, at 12:00 p.m. ET.

A live webcast of the fireside chat will be available on the Investors section of the Viracta website under '[Events and Webcasts](#)' and archived for 30 days.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV<sup>+</sup>) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV<sup>+</sup> recurrent or metastatic nasopharyngeal carcinoma and other EBV<sup>+</sup> solid tumors. Viracta is also pursuing the application of its "*Kick and Kill*" approach in other virus-related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Investor Relations Contact:**

Ashleigh Barreto  
Head of Investor Relations & Corporate Communications  
Viracta Therapeutics, Inc.  
[abarreto@viracta.com](mailto:abarreto@viracta.com)

SOURCE Viracta Therapeutics, Inc.

---

<https://viracta.investorroom.com/2023-03-08-Viracta-Therapeutics-to-Present-at-the-33rd-Annual-Oppenheimer-Healthcare-Conference>